April 20, 2004Pharmos Corp • March 10th, 2005 • Pharmaceutical preparations
Mr. Robert W. Cook [Home Address] Dear Bob: This letter sets forth our entire agreement regarding your separation as the Executive Vice President and Chief Financial Officer of Pharmos Corporation (the “Company”), notwithstanding the provisions of your Employment Agreement dated as of April 2, 2001, as amended (the “Employment Agreement”). This letter supersedes the Employment Agreement, and to the extent there is any inconsistency between the terms of the Employment Agreement and this letter agreement, the terms hereof will govern. We have agreed as follows: 1. Resignation. The Company and you each acknowledge that you effectively gave us notice of your resignation on March 22, 2004. We have agreed that you will remain as an employee of the Company through April 22, 2004, at which time you will relinquish your duties as Executive Vice President and Chief Financial Officer of the Company. Thereafter, you will serve as a paid consultant to the Company through May 22, 2004, assisting ma
Re: Amendment of Employment Agreement Dear Gadi:Pharmos Corp • March 10th, 2005 • Pharmaceutical preparations
ContractAsset Purchase Agreement • March 10th, 2005 • Pharmos Corp • Pharmaceutical preparations • New York
Exhibit 10(v) AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT This Amendment No. 2 to Asset Purchase Agreement dated as of December 30, 2004 (“Amendment No. 2”) between Bausch & Lomb Incorporated, a New York corporation with its principal place of business at One Bausch & Lomb Place, Rochester, NY 14604-2701 (“Buyer”) and Pharmos Corporation, a Nevada corporation with its principal place of business at 99 Wood Avenue South, Suite 311, Iselin, NJ 08830 (“Seller”). WHEREAS, Buyer and Seller entered into the Asset Purchase Agreement dated as of October 9, 2001, as amended by Amendment No. 1 to Asset Purchase Agreement dated as of December 28, 2001 (collectively the “Asset Purchase Agreement”); and WHEREAS, Buyer and Seller desire to amend the Asset Purchase Agreement to provide the final amount of the First Contingent Payment and the final LE-T R&D Costs (each as defined in the Asset Purchase Agreement). NOW, THEREFORE, in consideration of the mutual agreements contained herein, and other goo
